ReviewClinical cancer research : an official journal of the American Association for Cancer Research2012
A new approach to reducing postsurgical cancer recurrence: perioperative targeting of catecholamines and prostaglandins.
Review in Clinical cancer research : an official journal of the American Association for Cancer Research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 112 citations in OpenAlex.
- Favorable safety outcomes of a perioperative propranolol and etodolac regimen in cancer patients in four randomized controlled trials.Frontiers in pharmacology · 2026Trial
- Effect of Perioperative Interleukin-6 and Tumor Necrosis Factor-Journal of immunology research · 2022Trial
- Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial.Blood advances · 2020Trial
- Intraoperative ketorolac in high-risk breast cancer patients. A prospective, randomized, placebo-controlled clinical trial.PloS one · 2019Trial
- Perioperative COX-2 and β-Adrenergic Blockade Improves Metastatic Biomarkers in Breast Cancer Patients in a Phase-II Randomized Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Trial
- Defining Early Recurrence in Resectable Non-small Cell Lung Cancer Using Post-Recurrence Survival.Lung · 2026Article
- Leveraging the perioperative window in pancreatic cancer: lessons from the PROSPER trial.Gland surgery · 2026Article
- Advances in intratumoral immunotherapy from a neuro-immune-endocrine perspective for breast cancer treatment.Frontiers in oncology · 2026Review
- Metabolomic Profiling of Erector Spinae Plane Block for Breast Cancer Surgery.Medicina (Kaunas, Lithuania) · 2025Article
- Surgical Resection of Murine PDAC Alters Hepatic Metastases and Immune Microenvironment.Pancreas · 2025Article
- The impact of perioperative anesthesia management-induced immunosuppression on postoperative cancer recurrence and metastasis: a narrative review.Frontiers in oncology · 2025Review
- Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Review
- Article
- Regional anesthesia is associated with improved metastasis free survival after surgical resection of bone sarcomas.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2023Article
- Increased sympathetic nervous system impairs prognosis in lung cancer patients: a scoping review of clinical studies.Lung cancer management · 2023Article
- Chronic stress-induced immune dysregulation in breast cancer: Implications of psychosocial factors.Journal of translational internal medicine · 2023Article
- Surgical Inflammation Alters Immune Response to Intraoperative Photodynamic Therapy.Cancer research communications · 2023Article
- Immunotherapy during the Immediate Perioperative Period: A Promising Approach against Metastatic Disease.Current oncology (Toronto, Ont.) · 2023Review
- Neurotransmitters: promising immune modulators in the tumor microenvironment.Frontiers in immunology · 2023Review
- Perioperative oncolytic virotherapy to counteract surgery-induced immunosuppression and improve outcomes in pancreatic ductal adenocarcinoma.Frontiers in oncology · 2023Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Surgery is a crucial intervention in most cancer patients, but the perioperative period is characterized by increased risks for future outbreak of preexisting micrometastases and the initiation of new metastases-the major cause of cancer-related death. Here we argue that the short perioperative period is disproportionately critical in determining long-term recurrence rates, discuss the various underlying risk factors that act synergistically during this period, and assert that this time frame presents an unexplored opportunity to reduce long-term cancer recurrence. We then address physiologic mechanisms that underlie these risk factors, focusing on excess perioperative release of catecholamines and prostaglandins, which were recently shown to be prominent in facilitating cancer recurrence through their direct impact on the malignant tissue and its microenvironment, and through suppressing antimetastatic immunity. The involvement of the immune system is further discussed in light of accumulating evidence in cancer patients, and given the recent identification of endogenously activated unique leukocyte populations which, if not suppressed, can destroy autologous "immune-resistant" tumor cells. We then review animal studies and human correlative findings, suggesting the efficacy of blocking catecholamines and/or prostaglandins perioperatively, limiting metastasis and increasing survival rates. Finally, we propose a specific perioperative pharmacologic intervention in cancer patients, based on simultaneous β-adrenergic blockade and COX-2 inhibition, and discuss specific considerations for its application in clinical trials, including our approved protocol. In sum, we herein present the rationale for a new approach to reduce long-term cancer recurrence by using a relatively safe, brief, and inexpensive intervention during the perioperative period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.